Tytgat Hanne L P, Douillard François P, Reunanen Justus, Rasinkangas Pia, Hendrickx Antoni P A, Laine Pia K, Paulin Lars, Satokari Reetta, de Vos Willem M
Laboratory of Microbiology, Wageningen University, Wageningen, The Netherlands
Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland.
Appl Environ Microbiol. 2016 Sep 16;82(19):5756-62. doi: 10.1128/AEM.01243-16. Print 2016 Oct 1.
Vancomycin-resistant enterococci (VRE) have become a major nosocomial threat. Enterococcus faecium is of special concern, as it can easily acquire new antibiotic resistances and is an excellent colonizer of the human intestinal tract. Several clinical studies have explored the potential use of beneficial bacteria to weed out opportunistic pathogens. Specifically, the widely studied Lactobacillus rhamnosus strain GG has been applied successfully in the context of VRE infections. Here, we provide new insight into the molecular mechanism underlying the effects of this model probiotic on VRE decolonization. Both clinical VRE isolates and L. rhamnosus GG express pili on their cell walls, which are the key modulators of their highly efficient colonization of the intestinal mucosa. We found that one of the VRE pilus clusters shares considerable sequence similarity with the SpaCBA-SrtC1 pilus cluster of L. rhamnosus GG. Remarkable immunological and functional similarities were discovered between the mucus-binding pili of L. rhamnosus GG and those of the clinical E. faecium strain E1165, which was characterized at the genome level. Moreover, E. faecium strain E1165 bound efficiently to mucus, which may be prevented by the presence of the mucus-binding SpaC protein or antibodies against L. rhamnosus GG or SpaC. These results present experimental support for a novel probiotic mechanism, in which the mucus-binding pili of L. rhamnosus GG prevent the binding of a potential pathogen to the host. Hence, we provide a molecular basis for the further exploitation of L. rhamnosus GG and its pilins for prophylaxis and treatment of VRE infections.
Concern about vancomycin-resistant Enterococcus faecium causing nosocomial infections is rising globally. The arsenal of antibiotic strategies to treat these infections is nearly exhausted, and hence, new treatment strategies are urgently needed. Here, we provide molecular evidence to underpin reports of the successful clinical application of Lactobacillus rhamnosus GG in VRE decolonization strategies. Our results provide support for a new molecular mechanism, in which probiotics can perform competitive exclusion and possibly immune interaction. Moreover, we spur further exploration of the potential of intact L. rhamnosus GG and purified SpaC pilin as prophylactic and curative agents of the VRE carrier state.
耐万古霉素肠球菌(VRE)已成为医院感染的主要威胁。屎肠球菌尤其值得关注,因为它很容易获得新的抗生素耐药性,并且是人类肠道的优良定植菌。多项临床研究探讨了利用有益菌清除机会性病原体的可能性。具体而言,被广泛研究的鼠李糖乳杆菌GG菌株已成功应用于VRE感染的治疗。在此,我们对这种模型益生菌在VRE去定植作用背后的分子机制提供了新的见解。临床VRE分离株和鼠李糖乳杆菌GG在其细胞壁上均表达菌毛,这些菌毛是它们高效定植于肠黏膜的关键调节因子。我们发现,一种VRE菌毛簇与鼠李糖乳杆菌GG的SpaCBA - SrtC1菌毛簇具有相当高的序列相似性。在鼠李糖乳杆菌GG与临床屎肠球菌菌株E1165(已在基因组水平进行了表征)的黏液结合菌毛之间发现了显著的免疫学和功能相似性。此外,屎肠球菌菌株E1165能有效地结合黏液,而黏液结合性SpaC蛋白或针对鼠李糖乳杆菌GG或SpaC的抗体的存在可能会阻止这种结合。这些结果为一种新的益生菌机制提供了实验支持,即鼠李糖乳杆菌GG的黏液结合菌毛可阻止潜在病原体与宿主的结合。因此,我们为进一步开发鼠李糖乳杆菌GG及其菌毛蛋白用于预防和治疗VRE感染提供了分子基础。
全球范围内,对耐万古霉素屎肠球菌引起医院感染的关注日益增加。治疗这些感染的抗生素策略几乎已用尽,因此迫切需要新的治疗策略。在此,我们提供分子证据以支持关于鼠李糖乳杆菌GG在VRE去定植策略中临床成功应用的报道。我们的结果为一种新的分子机制提供了支持,即益生菌可进行竞争性排斥并可能发生免疫相互作用。此外,我们促使进一步探索完整的鼠李糖乳杆菌GG和纯化的SpaC菌毛蛋白作为VRE携带状态的预防和治疗剂的潜力。